Abstract:Traditional cancer therapies, such as surgery treatment, radiotherapy, and chemotherapy, often fail to completely eliminate tumor cells in an anaerobic microenvironment of tumor regions. In contrast to these traditional cancer therapies, the use of targeted delivery vectors to deliver anticancer genes or antitumor drugs to hypoxic areas in tumors is the most clinically promising cancer treatment with rapid development in recent years. In this study, E.coli Nissle 1917 (EcN), an intestinal probiotic, was utilized as a targeted transport vector to deliver p53 and Tum-5 protein to tumor hypoxic regions. The tumor-targeting characteristics of EcN were investigated using luciferase Lux CDABE operon, and the results demonstrated that EcN could specifically accumulate in the solid tumor areas of SMMC-7721 tumor-bearing BALB/c nude mice. The Tum 5-p53 bifunctional proteins were initially constructed and then delivered to solid tumor regions by using the targeted transporter EcN for cancer therapy. The antitumor effect and safety of three engineered bacteria, namely, EcN (Tum-5), EcN (p53), and EcN (Tum 5-p53), were also examined. The calculated tumor volume and tumor weight indicated that these three engineered bacteria could inhibit the growth of human hepatoma SMMC-7721 cells, and the antitumor effect of EcN (Tum 5-p53) expressing the Tum 5-p53 fusion protein was significantly better than those of EcN (Tum-5) and EcN (p53) alone. Immunofluorescence demonstrated that the expression of Ki-67, a nuclear proliferation-related protein, was inhibited in the tumor areas of the groups treated with the engineered bacteria, whereas the expression of caspase-3 was upregulated. The expression trends of Ki-67 and caspase-3 were consistent with the different antitumor efficacies of these three engineered bacteria. EcN did not elicit obvious side effects on mice. This research not only provids a foundation for tumor-targeted therapy but also contributes greatly to the development of antitumor agents and anticancer proteins.

Hypoxic Tumor Radiosensitization Using Engineered Probiotics

Self-adjusting Engineered Probiotic for Targeted Tumor Colonization and Local Therapeutics Delivery

Probiotic Engineering and Targeted Sonoimmuno-Therapy Augmented by STING Agonist.

Engineering Clinically Relevant Probiotics with Switchable "nano‐promoter" and "nano‐effector" for Precision Tumor Therapy

Genetically engineered probiotics for an optical imaging-guided tumor photothermal therapy/immunotherapy

Nanoparticles Conjugated with Bacteria Targeting Tumors for Precision Imaging and Therapy.

Oxygen-evolving Photosynthetic Cyanobacteria for 2D Bismuthene Radiosensitizer-Enhanced Cancer Radiotherapy.

Engineering probiotic biohydrogen micro-factories to initiate reductive stress for boosting tumor vulnerability

In-situ synthesis of melanin in tumor with engineered probiotics for hyperbaric oxygen-synergized photothermal immunotherapy

Metabolic engineering of probiotic Escherichia coli for cytolytic therapy of tumors

Bacteria-assisted Delivery and Oxygen Production of Nano-Enzyme for Potent Radioimmunotherapy of Cancer

Chemically Enhanced Live Probiotic for in Vivo Tumor Targeting and Inhibition

Engineered probiotic E.coli Nissle 1917 for release PTEN to improve the tumor microenvironment and suppress tumor growth

Engineering Micro Oxygen Factory to Slow Tumor Progression by Hyperoxia Microenvironment

Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments

Engineered Bacterial Bioreactor for Tumor Therapy Via Fenton‐Like Reaction with Localized H2O2 Generation

Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy

Genetically modified bacteria for targeted phototherapy of tumor

The role of bacteria and its derived biomaterials in cancer radiotherapy

Tweak to Treat: Reprograming Bacteria for Cancer Treatment

Bright Bacterium for Hypoxia‐Tolerant Photodynamic Therapy Against Orthotopic Colon Tumors by an Interventional Method